+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

In vitro and in vivo evaluation of BO-2727 against imipenem- and/or meropenem-resistant Pseudomonas aeruginosa



In vitro and in vivo evaluation of BO-2727 against imipenem- and/or meropenem-resistant Pseudomonas aeruginosa



Journal of Antibiotics 50(2): 135-138



The in vitro and in vivo activity of BO-2727, a carbapenem antibiotic, against resistant clinical isolates of Pseudomonas aeruginosa was studied. The geometric mean MICs against three groups of clinical isolates resistant to imipenem, meropenem and both carbapenems were 4.28, 4.08 and 5.44 micrograms/ml, respectively. BO-2727 also inhibited multiply antibiotic resistant isolates and laboratory mutants including a nalB-type mutant, which showed resistance to antibiotics such as imipenem, meropenem, ceftazidime, and/or ciprofloxacin, at less than 1.56 micrograms/ml. Overall, BO-2727 was 4-fold more active than biapenem, meropenem, panipenem and imipenem with an MIC90 of less than 6.25 micrograms/ml. The presence of basic amino acids in minimal medium less affected the antipseudomonal activity to a minimal extent, suggesting that BO-2727 has diverse penetration routes through the outer membrane other than OprD channel, which facilitates the diffusion of basic amino acids and carbapenems. The in vitro activity of BO-2727 reflected well in its therapeutic efficacy in experimental systemic infection in mice. These results suggest a possibility for the development of antipseudomonal carbapenems having activity against imipenem- and/or meropenem-resistant P. aeruginosa as well as a broad spectrum encompassing Gram-positive and -negative bacteria.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 008835746

Download citation: RISBibTeXText

PMID: 9099222

DOI: 10.7164/antibiotics.50.135


Related references

Antipseudomonal activity of BO-2727 against imipenem- and/or meropenem-resistant Pseudomonas aeruginosa. Abstracts of the Interscience Conference on Antimicrobial Agents and Chemotherapy 34: 30, 1994

Comparative in vitro activity of meropenem against pseudomonas aeruginosa and pseudomonas maltophilia isolated from cystic fibrosis patients including imipenem resistant strains. Abstracts of the General Meeting of the American Society for Microbiology 91: 3, 1991

In-vitro activity of meropenem, a new carbapenem, against imipenem-resistant Pseudomonas aeruginosa and Xanthomonas maltophilia. Journal of ChemoTherapy 3(3): 143-146, 1991

The comparison of in the vitro effect of imipenem or meropenem combined with ciprofloxacin or levofloxacin against multidrug-resistant Pseudomonas aeruginosa strains. International Journal of Antimicrobial Agents 20(5): 384-386, 2002

In vitro antibacterial activity of rifampicin in combination with imipenem, meropenem and doripenem against multidrug-resistant clinical isolates of Pseudomonas aeruginosa. Bmc Infectious Diseases 16(1): 444, 2016

Comparative in vitro pharmacodynamics of imipenem and meropenem against Pseudomonas aeruginosa. Antimicrobial Agents and ChemoTherapy 40(4): 904-908, 1996

Successful treatment with doripenem and tobramycin of ventriculitis due to imipenem- and meropenem-resistant Pseudomonas aeruginosa. Journal of Antimicrobial ChemoTherapy 63(6): 1297-1299, 2009

Molecular Characterization of Imipenem-Resistant, Meropenem-Susceptible Pseudomonas aeruginosa with blaVIM₋₂ Phenotype: Potential for Dissemination. Japanese Journal of Infectious Diseases 69(2): 159-160, 2016

In-vitro interactions of DX-8739, a new carbapenem, meropenem and imipenem with amikacin against multiresistant Pseudomonas aeruginosa. Journal of Antimicrobial ChemoTherapy 38(2): 287-291, 1996

Comparative in vitro interactions of ceftazidime, meropenem, and imipenem with amikacin on multiresistant Pseudomonas aeruginosa. Diagnostic Microbiology and Infectious Disease 29(2): 81-86,., 1997

Comparative in vitro killing activity of meropenem versus imipenem against multiresistant nosocomial Pseudomonas aeruginosa. Journal of ChemoTherapy 7(3): 179-183, 1995

Evaluation of the In Vitro Activity of Ceftazidime-Avibactam and Ceftolozane-Tazobactam against Meropenem-Resistant Pseudomonas aeruginosa Isolates. Antimicrobial Agents and ChemoTherapy 60(5): 3227-3231, 2016

In-vitro activity of biapenem, compared with imipenem and meropenem, against Pseudomonas aeruginosa strains and mutants with known resistance mechanisms. Journal of Antimicrobial ChemoTherapy 33(5): 949-958, 1994

In vitro activity of meropenem, imipenem, cefepime and ceftazidime against Pseudomonas aeruginosa isolates from cystic fibrosis patients. Journal of Antimicrobial ChemoTherapy 45(6): 899-901, 2000

In vitro activity and killing effect of DX-8739, a new carbapenem, compared with those of meropenem and imipenem against multiresistant Pseudomonas aeruginosa. Antimicrobial Agents and ChemoTherapy 39(3): 731-734, 1995